A gene-editing tool delivery vector and its application in NK cells
By using a fusion peptide vector containing cell-penetrating peptides and antimicrobial peptides to deliver proteins from the CRISPR/Cas system or the Cre-loxP recombinant system, the toxicity and efficiency issues in NK cell gene editing have been resolved, achieving efficient and safe gene editing and supporting NK cell engineering and CAR-NK immunotherapy.
Patent Information
- Application Number
- CN202611183210.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-05
- Publication Date
- 2026-11-17
AI Technical Summary
Existing gene editing tools have limitations in delivery methods to NK cells due to issues such as immunogenicity, cytotoxicity, and low editing efficiency, which restrict the development of NK cell engineering and CAR-NK immunotherapy.
Using peptide carriers, especially fusion peptides of cell-penetrating peptides and antimicrobial peptides (such as TAT-AMP), to assist protein delivery in CRISPR/Cas systems or Cre-loxP recombinant systems can reduce toxic damage to NK cells and improve gene editing efficiency.
This achievement enables highly efficient and low-toxicity gene editing of NK cells, overcoming delivery bottlenecks and providing key technical support for NK cell engineering and CAR-NK immunotherapy.
Smart Images

Figure CN123106922A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of gene editing technology, specifically to a gene editing tool delivery vector and its application in NK cells. Background Technology
[0002] Natural killer (NK) cells are core members of the innate immune system, capable of rapidly recognizing and eliminating tumor cells and virus-infected cells in the absence of pre-sensitization, playing an irreplaceable role in anti-tumor immune surveillance. Adoptive immunotherapy based on NK cells has received widespread attention from academia and industry in recent years due to its lower risk of graft-versus-host disease and broad-spectrum anti-tumor activity. However, the anti-tumor activity of natural NK cells in vivo is limited, and the tumor microenvironment often inhibits NK cell function through multiple mechanisms. Therefore, it is necessary to engineer NK cells using gene editing technology to promote the development of "universal" NK cell products.
[0003] One of the core bottlenecks in the application of gene editing technology in NK cells lies in the efficient and safe delivery of editing tools (including CRISPR / Cas systems and Cre-loxP recombination systems) into NK cells. Currently, conventional methods for delivering gene editing tools to NK cells include viral vector systems, electroporation technology, polymer vectors, and lipid nanoparticles. However, all of these methods have revealed a series of defects that seriously restrict clinical translation in NK cell applications.
[0004] Viral vector systems are immunogenic, easily triggering host immune responses and clearing transduced cells. Furthermore, vectors such as adeno-associated viruses have limited packaging capacity, making it difficult to accommodate intact CRISPR / Cas elements. Electroporation technology causes significant damage to cells; NK cell survival rates decrease significantly after electroporation, and surviving cells often exhibit proliferation arrest and functional decline. Lipid nanoparticles have unstable editing efficiency; ionizable lipids and PEGylated lipid components can activate complement and innate immune pathways, triggering accelerated blood clearance and hypersensitivity reactions. Moreover, intravenous administration easily leads to liver accumulation, accompanied by hepatotoxicity risks.
[0005] Given the limitations of the aforementioned methods, peptide delivery vectors, with their advantages of well-defined structures and low immunogenicity, have gradually become a research hotspot for novel non-viral vectors for delivering CRISPR / Cas systems or Cre-loxP recombinant systems. Existing literature has reported several delivery systems based on cell-penetrating peptides or endosome-escape peptides, capable of introducing CRISPR / Cas9 ribonucleoprotein complexes into various cell lines. However, the performance of existing peptides used for gene editing delivery in NK cells is far from ideal: on the one hand, their delivery efficiency is insufficient to achieve therapeutic-grade gene editing positivity rates in NK cells; on the other hand, some peptides disrupt the integrity of the NK cell membrane at delivery concentrations, inducing significant cytotoxicity and resulting in low viable cell recovery rates. This severely restricts the possibility of further using gene-edited NK cells for CAR-NK formulation preparation and large-scale application. Summary of the Invention
[0006] This invention aims to at least partially address one of the technical problems in related technologies. Therefore, one objective of this invention is to provide a polypeptide that is a superior candidate molecule capable of efficiently mediating transmembrane transport via the CRISPR / Cas system or the Cre-loxP recombinant system, while exhibiting no significant toxicity to NK cells. This polypeptide can be used as a core delivery vector to construct an NK cell gene editing system, aiming to overcome the current delivery bottleneck in NK cell gene editing and provide key technical support for the efficient, safe, and scalable engineering of NK cells and the development of CAR-NK immunotherapy products.
[0007] Therefore, the first aspect of the present invention provides a polypeptide. According to embodiments of the present invention, the amino acid sequence of the polypeptide is as shown in SEQ ID NO: 2-23, or is a derived sequence having the same function as the amino acid sequence shown in SEQ ID NO: 2-23.
[0008] The inventors screened out a polypeptide sequence that includes a cell-penetrating peptide and an antimicrobial peptide amino acid sequence. This polypeptide can assist the delivery of the Cas protein and its ribonucleoprotein complex (RNP) with sgRNA or crRNA in the CRISPR / Cas gene editing system into the target cell, or assist the delivery of the Cre protein in the Cre-loxP recombination system into the target cell, while reducing damage to the cell and having almost no impact on the cell's inherent characteristics and state.
[0009] According to a preferred embodiment of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 20.
[0010] According to a further preferred embodiment of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 14 and SEQ ID NO: 16.
[0011] A second aspect of the present invention provides an isolated nucleic acid. According to embodiments of the present invention, the nucleic acid encodes the polypeptide described in the first aspect.
[0012] A third aspect of the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector comprises the isolated nucleic acid described in the second aspect.
[0013] A fourth aspect of the present invention provides a host cell. According to an embodiment of the present invention, the host cell comprises the expression vector described in the third aspect.
[0014] The fifth aspect of this invention provides the use of the polypeptide described in the first aspect, the isolated nucleic acid described in the second aspect, the expression vector described in the third aspect, and the host cell described in the fourth aspect in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system.
[0015] The sixth aspect of this invention provides the use of the polypeptide described in the first aspect, the isolated nucleic acid described in the second aspect, the expression vector described in the third aspect, and the host cell described in the fourth aspect in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system of NK cells.
[0016] The seventh aspect of this invention provides the use of the polypeptide described in the first aspect, the isolated nucleic acid described in the second aspect, the expression vector described in the third aspect, and the host cell described in the fourth aspect in the preparation of reagents or kits for improving the gene editing efficiency of CRISPR / Cas systems or Cre-loxP recombination systems for NK cells.
[0017] An eighth aspect of the present invention provides a reagent or kit for improving the gene editing efficiency of a CRISPR / Cas system or a Cre-loxP recombination system in NK cells. According to embodiments of the present invention, the reagent or kit comprises at least one of the following: The polypeptide described in the first aspect, the isolated nucleic acid described in the second aspect, the expression vector described in the third aspect, and the host cell described in the fourth aspect.
[0018] A ninth aspect of the present invention provides a method for improving the gene editing efficiency of a CRISPR / Cas system or a Cre-loxP recombination system for NK cells. According to an embodiment of the present invention, the method includes the following (1) or (2): (1) The polypeptide described in the first aspect is mixed with the delivery cargo to obtain a mixture; The mixture was introduced into NK cells; The delivered goods include at least one of the following: (a) A CRISPR system effector protein, or a complex formed by sgRNA or crRNA targeting a gene and the CRISPR system effector protein; (b) Vectors expressing CRISPR system effector proteins, and sgRNA or crRNA targeting the target gene; (c) CRISPR system effector proteins, and vectors expressing sgRNA or crRNA that target the gene; (d) Vectors that co-express CRISPR system effector proteins and sgRNA or crRNA targeting the target gene. (2) The polypeptide described in the first aspect is mixed with Cre recombinase or a derivative of Cre protein to obtain a mixture; The mixture was introduced into NK cells; The NK cells contain a pre-designed loxP site.
[0019] Beneficial effects: The peptides of this invention can enhance the efficiency of gene editing in NK cell lines and primary cells with high efficiency, low toxicity, and low perturbation. This invention also provides a method for improving the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system in NK cells, which can efficiently mediate the transmembrane transport of the CRISPR / Cas system or the Cre-loxP recombination system while causing no significant toxic damage to NK cells. Constructing an NK cell gene editing system using the peptide sequence of this invention as the core delivery vector aims to overcome the current delivery bottleneck in NK cell gene editing, providing key technical support for efficient, safe, and scalable NK cell engineering and the development of CAR-NK immunotherapy products.
[0020] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description
[0021] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which: Figure 1 A schematic diagram of the TAT-AMP delivery Cas12a RNP editing system in Example 2 is shown. Figure 2 The efficiency of 100 μM TAT-HA2 and TAT-AMP in delivering Cas12aRNP in human primary NK cells is shown in Example 2, where A is the delivery efficiency result graph; B is the flow cytometry result graph. Figure 3 The cytotoxicity of 100 μM TAT-HA2 and TAT-AMP in human primary NK cells after delivery of Cas12aRNP in Example 2 is shown. Figure 4 The total number of edited live cells obtained after delivery of Cas12a RNP to human primary NK cells with 100 μM TAT-HA2 and TAT-AMP in Example 2 is shown. Figure 5 This shows an overall schematic diagram of TAT-AMP delivery of the Cas9 protein in Example 2; Figure 6 The efficiency and cytotoxicity of 75 μM TAT-HA2 and TAT-AMP in NK92 mCherry cells for Cas9 protein delivery in Example 2 are shown. In the figure, A is the delivery efficiency result; B is the cell viability result. Figure 7 The total number of edited live cells obtained after Cas9 protein delivery in NK92 mCherry cells with 75 μM TAT-HA2 and TAT-AMP in Example 2 is shown. Figure 8 The efficiency and cytotoxicity of 125 μM TAT-HA2 and TAT-AMP in NK92 mCherry cells for Cas9 protein delivery in Example 2 are shown. In the figure, A is the delivery efficiency result; B is the cell viability result. Figure 9 The total number of edited live cells obtained after Cas9 protein delivery in NK92 mCherry cells with 125 μM TAT-HA2 and TAT-AMP in Example 2 is shown. Figure 10 The efficiency and cytotoxicity of different concentrations of TAT-HA2 and TAT-AMP in delivering Cas12a RNP to Ai9 mouse NK cells are shown in Example 2. In this figure, A is the delivery efficiency result; B is the viable cell rate result. Figure 11The total number of edited live cells obtained after delivering Cas12a RNP to NK cells of Ai9 mice with different concentrations of TAT-HA2 and TAT-AMP in Example 2 is shown. Figure 12 The efficiency and cytotoxicity of 50 μM and 75 μM TAT-HA2 and TAT-AMP in the delivery of TAT-NLS-Cre to Ai9 mouse NK cells are shown in Example 2. In the figure, A is the delivery efficiency result; B is the viable cell rate result. Figure 13 The total number of edited live cells obtained after delivering TAT-NLS-Cre to Ai9 mouse NK cells with 50 μM and 75 μM TAT-HA2 and TAT-AMP in Example 2 is shown. Figure 14 This shows an overall schematic diagram of gene editing using TAT-AMP delivered to mouse muscle via Cas12a RNP in Example 2; Figure 15 The delivery efficiency of TAT-HA2 and TAT-AMP to Cas12a RNP in mouse muscle is shown in Example 2, where A is the fluorescence graph in mouse muscle; B is the statistical bar graph of fluorescence intensity. Detailed Implementation
[0022] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0023] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this invention, unless otherwise stated, "a plurality of" means two or more.
[0024] The endpoints and any values of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of the various ranges, the endpoint values of the various ranges and individual point values, and individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.
[0025] To facilitate understanding of the invention, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains.
[0026] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.
[0027] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.
[0028] This invention first uses bioinformatics to predict the sequence of an antimicrobial peptide (AMP) with endosome escape capability, and synthesizes a fusion polypeptide (TAT-AMP) of the cell-penetrating peptide TAT and the antimicrobial peptide (AMP), giving it dual functions of cell penetration and endosome escape: it can efficiently and relatively gently deliver the CRISPR / Cas system into NK cells and promote the endosome escape of the CRISPR / Cas system in the cytoplasm, thereby improving its nuclear entry capability and gene editing. Secondly, the delivery effect of the fusion polypeptide (TAT-AMP) on the CRISPR / Cas system in primary cells and cell lines is tested. Finally, fusion peptide vector sequences for delivering the CRISPR / Cas system are screened to obtain the polypeptide sequence of this invention.
[0029] According to a specific embodiment of the present invention, the present invention provides a polypeptide, the amino acid sequence of which is shown in SEQ ID NO: 2-23, or a derived sequence having the same function as the amino acid sequence shown in SEQ ID NO: 2-23.
[0030] In this document, "derived sequence" in the context of derived sequences having the same function as the amino acid sequences shown in SEQ ID NO: 2-23 refers to a polypeptide sequence derived from SEQ ID NO: 2-23 that has undergone substitution, deletion, or addition of one or more amino acids in regions other than specific functional domains (such as active sites) of the amino acid sequences shown in SEQ ID NO: 2-23, but has the same activity as these amino acid sequences.
[0031] According to a specific embodiment of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 20.
[0032] According to a preferred embodiment of the present invention, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 14 and SEQ ID NO: 16.
[0033] According to a specific embodiment of the present invention, the present invention provides an isolated nucleic acid that encodes the aforementioned polypeptide.
[0034] According to a specific embodiment of the present invention, the present invention provides an expression vector comprising the isolated nucleic acid described above.
[0035] According to a specific embodiment of the present invention, the present invention provides a host cell comprising the expression vector described above.
[0036] According to a specific embodiment of the present invention, the present invention provides the use of the aforementioned polypeptide, the aforementioned isolated nucleic acid, the aforementioned expression vector, and the aforementioned host cell in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system.
[0037] According to a specific embodiment of the present invention, the Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein; the Cre protein involved in the Cre-loxP recombination system is a Cre recombinase or a derivative of the Cre protein.
[0038] According to a specific embodiment of the present invention, the CRISPR system effector proteins include, but are not limited to, one or more of Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl.
[0039] According to a specific embodiment of the present invention, the derivative of the Cas protein includes a base editor and a bootstrap editor.
[0040] According to a specific embodiment of the present invention, the derivative of the Cre protein includes one or more of TAT-NLS-Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
[0041] According to a specific embodiment of the present invention, the present invention provides the use of the aforementioned polypeptide, the aforementioned isolated nucleic acid, the aforementioned expression vector, and the aforementioned host cell in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system of NK cells.
[0042] In this article, "NK cells" include, but are not limited to, primary NK cells, NK cell lines, and engineered NK cells (such as CAR-NK cells).
[0043] According to a specific embodiment of the present invention, the present invention provides the use of the aforementioned polypeptide, the aforementioned isolated nucleic acid, the aforementioned expression vector, and the aforementioned host cell in the preparation of reagents or kits for improving the gene editing efficiency of CRISPR / Cas systems or Cre-loxP recombination systems for NK cells.
[0044] According to a specific embodiment of the present invention, the present invention provides a reagent or kit for improving the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system in NK cells, comprising at least one of the following: The aforementioned polypeptide, the aforementioned isolated nucleic acid, the aforementioned expression vector, and the aforementioned host cell.
[0045] According to a specific embodiment of the present invention, the Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein.
[0046] According to a specific embodiment of the present invention, the CRISPR system effector proteins include, but are not limited to, one or more of Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl.
[0047] According to a specific embodiment of the present invention, the Cre protein involved in the Cre-loxP recombination system is a Cre recombinase or a derivative of the Cre protein.
[0048] According to a specific embodiment of the present invention, the Cre protein includes, but is not limited to, one or more of TAT-NLS-Cre, Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
[0049] According to a specific embodiment of the present invention, the reagent or kit further comprises delivery of cargo or TAT-NLS-Cre protein. The delivered goods include at least one of the following: (a) A CRISPR system effector protein, or a complex formed by sgRNA or crRNA targeting a gene and the CRISPR system effector protein; (b) Vectors expressing CRISPR system effector proteins, and sgRNA or crRNA targeting the target gene; (c) CRISPR system effector proteins, and vectors expressing sgRNA or crRNA that target the gene; (d) Vectors that co-express CRISPR system effector proteins and sgRNA or crRNA targeting target genes.
[0050] According to a specific embodiment of the present invention, the amino acid sequence of the TAT-NLS-Cre protein is shown in SEQ ID NO: 27.
[0051] It should be noted that the reagent may also contain other components, and the kit may also contain other reagents, all of which are covered within the scope of protection of this invention.
[0052] According to a specific embodiment of the present invention, the present invention provides a method for improving the gene editing efficiency of the CRISPR / Cas system for NK cells, the method comprising: The aforementioned polypeptide is mixed with the delivery cargo to obtain a mixture; The mixture was introduced into NK cells; The delivered goods include at least one of the following: (a) A CRISPR system effector protein, or a complex formed by sgRNA or crRNA targeting a gene and the CRISPR system effector protein; (b) Vectors expressing CRISPR system effector proteins, and sgRNA or crRNA targeting the target gene; (c) CRISPR system effector proteins, and vectors expressing sgRNA or crRNA that target the gene; (d) Vectors that co-express CRISPR system effector proteins and sgRNA or crRNA targeting target genes.
[0053] According to a specific embodiment of the present invention, the present invention provides a method for improving the gene editing efficiency of the Cre-loxP recombination system in NK cells, the method comprising: The aforementioned polypeptide is mixed with Cre recombinase or a derivative of Cre protein to obtain a mixture; The mixture was introduced into NK cells; The NK cells contain a pre-designed loxP site.
[0054] Cre-loxP recombination is a site-specific recombinase technology that can perform deletion, insertion, translocation, and inversion at specific sites (loxP sites) in DNA. This system can be used to modify DNA in cells for specific cell types (such as NK cells) or by using specific external stimuli (such as light of a specific wavelength).
[0055] According to a specific embodiment of the present invention, the CRISPR system effector proteins include, but are not limited to, one or more of Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl.
[0056] According to a specific embodiment of the present invention, the derivatives of the Cre protein include, but are not limited to, one or more of TAT-NLS-Cre, Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
[0057] According to a more specific embodiment of the present invention, when the CRISPR system effector protein is Cas12a protein, the method for improving the gene editing efficiency of the CRISPR / Cas system in NK cells includes the following steps: (1) Prepare a complex RNP containing Cas12a protein and crRNA in vitro, wherein the crRNA is designed to target a gene; the molar ratio of Cas12a protein to crRNA can be (1-2):1, preferably 1.25:1; (2) The complex is mixed with the polypeptide (TAT-AMP) and primary NK cells or NK cell lines and incubated to obtain gene-edited target cells, and the gene editing efficiency in the target cells is significantly improved compared with the gene editing method without TAT-AMP.
[0058] It should be noted that the peptide (TAT-AMP) and Cas12a RNP can be mixed before incubation. There are no particular restrictions on the culture conditions, Cas12a protein concentration, peptide concentration, or cell concentration during incubation. Preferably, the final concentration of the peptide TAT-AMP is 10-150 μM; the final concentration of the Cas12a protein can be 6.25 μM; the temperature is 37°C; and the incubation time is 30 min. The incubation temperature and time can be adjusted as needed.
[0059] According to a more specific embodiment of the present invention, when the CRISPR system effector protein is Cas9 protein, the method for improving the gene editing efficiency of the CRISPR / Cas system includes the following steps: (1) Introduce a vector that expresses sgRNA designed to target the gene into primary NK cells or NK cell lines to obtain modified target cells; (2) The modified target cells are mixed and incubated with Cas9 protein and the polypeptide (TAT-AMP) of the present invention to obtain gene-edited primary NK cells or NK cell lines, and the gene editing efficiency of the primary NK cells or NK cell lines is significantly improved compared with the gene editing method without TAT-AMP.
[0060] It should be noted that during mixed incubation, the peptide TAT-AMP and Cas9 can be mixed first, or Cas9 and cells can be mixed first, and then the peptide can be added. There are no particular restrictions on the culture conditions, Cas9 protein concentration, peptide concentration, and cell concentration during incubation. Preferably, the final concentration of the peptide TAT-AMP is 50-150 μM; the final concentration of the Cas9 protein is 0.5 μM; the temperature is 37°C; and the incubation time is 30 min. The incubation temperature and time can be adjusted as needed.
[0061] According to a specific embodiment of the present invention, when the Cre protein involved in the Cre-loxP recombination system is TAT-NLS-Cre, the method for improving the gene editing efficiency of the Cre-loxP recombination system in cells (in vitro) includes the following steps: (1) Introduce loxP sites designed to target DNA fragments or target genes into primary NK cells or NK cell lines to obtain modified target cells; (2) The modified target cells are mixed and incubated with TAT-NLS-Cre protein and the polypeptide (TAT-AMP) of the present invention to obtain primary NK cells or NK cell lines edited by the Cre-loxP recombination system, and the gene editing efficiency of the primary NK cells or NK cell lines is significantly improved compared with the gene editing method without TAT-AMP.
[0062] It should be noted that during mixed incubation, the peptide TAT-AMP and TAT-NLS-Cre protein can be mixed first, or the TAT-NLS-Cre protein and cells can be mixed first, and then the peptide is added. There are no particular restrictions on the culture conditions, TAT-NLS-Cre protein concentration, peptide concentration, and cell concentration during incubation. Preferably, the final concentration of the peptide TAT-AMP is 50-75 μM; the final concentration of the TAT-NLS-Cre protein is 1 μM; the temperature is 37°C; and the incubation time is 30 min. The incubation temperature and time can be adjusted as needed.
[0063] According to a specific embodiment of the present invention, when the CRISPR system effector protein is Cas12a protein, the method for improving the gene editing efficiency of the CRISPR / Cas system in muscle (in vivo) includes the following steps: (1) Prepare a complex RNP containing Cas12a protein and crRNA in vitro, wherein the crRNA is designed to target a gene; the molar ratio of Cas12a protein to crRNA can be (1-2):1, preferably 1.25:1; (2) The complex and the polypeptide (TAT-AMP) were injected into the muscle of mice to obtain gene-edited muscle tissue, and the gene editing efficiency in the muscle tissue was significantly improved compared with the gene editing method without TAT-AMP.
[0064] It should be noted that during the mixed incubation, the peptide (TAT-AMP) and Cas12a RNP can be mixed first. There are no particular restrictions on the concentration of Cas12a protein, peptide, or injection volume when administering intramuscular injection. Preferably, the final concentration of the peptide TAT-AMP is 75 μM; the final concentration of the Cas12a protein can be 6.25 μM; and the injection volume of the RNP and peptide complex is 50 μL. Editing efficiency is observed 7 days after injection. The concentrations of the peptide and RNP, injection volume, and post-injection waiting time can be adjusted as needed.
[0065] The present disclosure will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be construed as limiting the scope of the disclosure. Where specific techniques or conditions are not specified in the embodiments, they are performed in accordance with the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0066] Example 1: Screening of AMP The antimicrobial peptides screened in this invention were derived from three publications: *Discovery of antimicrobial peptides in the global microbiome with machine learning*, *Mining human microbiomes reveals an untapped source of peptide antibiotics*, and *Global marine microbial diversity and its potential in bioprospecting*. A total of 299 antimicrobial peptide sequences were collected. The peptide sequence length was selected to be 25-30 amino acid residues; sequences that are too short are not conducive to maintaining a stable structure and penetrating cells. 133 sequences with a length of 25 amino acid residues or less, and 136 sequences with a length between 26 and 35 amino acid residues, were selected for further screening.
[0067] By predicting AMP activity, isoelectric point, toxicity, and secondary structure, positively charged, structurally stable, and non-toxic polypeptide sequences were screened. Sequences containing fewer Q, N, C, D, and E amino acid residues were preferentially selected. The screened AMP sequences (<25 amino acid residues) were linked with TAT (SEQ ID NO: 2-19), and AMP sequences with 25-30 amino acid residues (SEQ ID NO: 20-23) were also selected, resulting in the polypeptide sequences shown in Table 1 below. SEQ ID NO: 1 is the published positive control polypeptide sequence (TAT-HA2).
[0068] Table 1
[0069] Example 2: Experimental screening of AMP sequences with high delivery efficiency 1. TAT-AMP delivery to RNP knockout human primary NK cells B2M Gene Primary NK cell extraction: NK cells were isolated from PBMCs using the EasySep™ Human NK Cell Isolation Kit (STEMCELL #17955) and then inoculated with Cell-Vive™ GMP NKp46 / CD2 Human NK Cell Activation Beads (BioLegend #422611). Cells were cultured and expanded at 37°C and 5% CO2. Cells were counted on days 6, 9, and 14 and measured at 1.0 × 10⁶ cells / year. 6Cells were cultured at a density of [number] cells / mL. Gene editing was performed on days 9-11 after the start of culture. (1) Dilute the Cas12a protein concentration to 25 μM using serum-free cell culture medium (RPMI 1640 medium); The Cas12a used in this application is a protein obtained by expression using the opCas12a-T8N (https: / / www.addgene.org / 199605 / ) vector, which has TAT-6×Myc NLS at the N-terminus and 2×SV40 NLS-sfGFP at the C-terminus; (2) Dilute crRNA to a concentration of 100 μM with DNase-free / RNase-free water, aliquot and store at -80℃; B2M The crRNA sequence of the gene is: UAAUUUCUACUCUUGUAGAUAAUUCUCUCUCCAUUCUUCA (SEQ ID NO: 24). (3) Dissolve the peptides in PBS solution to 1 mM, filter sterilize using a 0.22 μm filter, aliquot and store at -80℃; (4) Dilute crRNA to a concentration of 20 μM using serum-free cell culture medium (RPMI 1640 medium); (5) Dilute the peptide to a concentration of 200 μM using serum-free cell culture medium (RPMI 1640 medium); (6) Mix the diluted Cas12a and diluted crRNA in equal volumes at a 1:1 ratio and let stand at room temperature for 20 min to prepare RNP (at this time, the concentration of crRNA is 10 μM, Cas12a is 12.5 μM, and the volume of RNP is generally not less than 10 μL). (7) Mix 10 μL of RNP and 10 μL of peptide to make a total of 20 μL, and let stand at room temperature for 5 min (at this time, the concentration of peptide is 100 μM, crRNA is 5 μM, Cas12a is 6.25 μM, and RNP is 5 μM). (8) Take 100-200K cells and centrifuge at 600×g for 3 min at room temperature to collect the cells. Wash the cells once with serum-free cell culture medium (RPMI 1640 medium) and centrifuge at 600×g for 3 min at room temperature to collect the cells; (9) Resuspend the cells in 20 μL of RNP+ polypeptide and incubate at 37℃ with 5% CO2 for 30 min. (10) Add 180 μL of complete culture medium (X-VIXO 15 containing 5% FBS, 50 μM 2-mercaptoethanol and 10 μM NAC) to terminate the knockout, and collect the cells by centrifugation at 600×g for 3 min at room temperature; (11) The cells were resuspended in 200 μL of complete culture medium containing 200 U / ml IL-2 and 5 ng / mL IL-15, and cultured in well plates. The knockout efficiency was detected by flow cytometry on the fourth day.
[0070] The above-mentioned TAT-AMP delivery to Cas12a knockout human primary NK cells B2M The process is as follows Figure 1 As shown in the middle route; Figure 2 The image shows TAT-HA2 (positive control peptide) as detected by flow cytometry and the peptide TAT-AMP (denoted as PeptideXX in the figure), which is composed of AMP linked to TAT as shown in Table 1. When using a final peptide concentration of 100 μM, most AMPs demonstrated the ability to deliver Cas12a RNPs in human primary NK cells, with peptides such as peptide47, peptide33, peptide37, peptide46, and peptide44 all achieving efficiencies exceeding 30%. Figure 2 (A). The delivery efficiencies of peptide46 and peptide44 were 74.7% and 76.8%, respectively, while the efficiency of TAT-HA2 was 64.4%, indicating that peptide44 and peptide46 have good delivery effects in human primary NK cells. Figure 2 (B)
[0071] Figure 3 The cytotoxicity of TAT-HA2 (positive control peptide) and TAT-AMP after delivery of Cas12a RNP in human primary NK cells was demonstrated. At a concentration of 100 μM, TAT-HA2 showed significant cytotoxicity, with a cell viability of only 5%. Most TAT-AMPs, however, exhibited less cytotoxicity, with peptides 44 and 46 showing particularly high efficacy, corresponding to cell viability rates of approximately 75% and 25%, respectively.
[0072] Figure 4 The results show the number of edited cells obtained after delivery of Cas12a RNP in human primary NK cells using TAT-HA2 (positive control peptide) and TAT-AMP. At a final peptide concentration of 100 μM, TAT-HA2 caused greater cell damage, resulting in a very low number of edited cells, only 0.4 × 10⁻⁶. 4 per cell. However, most TAT-AMPs have low toxicity, with peptide 44 and peptide 37 showing particularly good toxicity; using peptide 44 can yield up to 1.1 × 10⁻⁶ cells. 5 With peptide 37, the maximum yield is 1.0 × 10⁶ cells. 5One cell, the remaining eight peptides such as peptide39, peptide45, peptide48, peptide46, peptide33, peptide32, peptide50 and peptide40 all obtained more edited cells than TAT-HA2.
[0073] 2. TAT-AMP delivery of fluorescent proteins in the Cas9 knockout NK92 mCherry reporter system Viral infection of NK92 cells: 600K NK92 cells were infected with different lentiviral gradients. The lentiviruses contained the U6-sgRNA-EFS-mCherry plasmid vector, with the sgRNA sequence as follows: GGAGCCGUAC AUGAACUGAGGUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUUGCUGGAAACAGCAAAGUGGCACCGAGUCGGUGCUUUU UUU. Experiments were performed using 6-well plates. 600K cells were added to each well, along with the above-mentioned gradient doses of virus solution and 2 μL of polybrene (2 mg / mL). The volume was then increased to 2 mL / well using NK92 mCherry complete medium. After centrifugation at 1750 rpm for 25 min at room temperature, the cells were incubated at 37℃ in a 5% CO2 incubator. 14 hours after infection, the culture medium was replaced with complete medium and cultured in a 37℃ 5% CO2 incubator to allow the plasmid to carry resistance expression. After 48 hours of culture, Blastidin S-HCl was added to a final concentration of 10 μg / mL, and resistance screening was performed for 10-14 days. (1) Use serum-free cell culture medium ( The Cas9 protein concentration was diluted to 10 μM in MEM medium (Cas9 protein was obtained by expression in the Cas9-T6N vector (https: / / www.addgene.org / 199604), which has TAT-4×MycNLS at the N-terminus and 2×SV40 NLS-sfGFP at the C-terminus). (2) Dissolve the peptides in PBS solution to 1 mM, filter sterilize using a 0.22 μm filter, aliquot and store at -80℃; (3) Collect NK92 mCherry cells at 200K and centrifuge at 600×g for 3 min at room temperature. Use serum-free cell culture medium ( Rinse the cells once with MEM medium, then centrifuge at 600×g for 3 min at room temperature to collect the cells; (4) Add the diluted Cas9 to the tube, then add 20 μL of cell suspension, and finally add the peptide. Incubate at 37°C with 5% CO2 for 30 min (at this time, the concentration of Cas9 is 0.5 μM, and the concentration of peptide is 75 μM and 125 μM). (5) Add 180 μL of complete culture medium (RPMI 1640 containing 12.5% FBS, 12.5% Horse serum, 50 μM 2-mercaptoethanol, 0.2 mM myo-Inositol, 0.02 mM folic acid and 1.5 g / L sodiumbicarbonate) to terminate the knockout, and collect the cells by centrifugation at 600 × g for 3 min at room temperature; (6) Resuspend the cells in 500 μL of complete culture medium containing 200 U / ml IL-2, and culture them in 24-well plates. On the fourth day, the percentage of mCherry negative cells was detected by flow cytometry to evaluate the gene knockout efficiency.
[0074] The above-described process of TAT-AMP delivery of Cas9 knockout NK92 mCherry fluorescent protein is as follows: Figure 5 As shown in the middle route.
[0075] Figure 6 The efficiency and cytotoxicity of 75 μM TAT-HA2 (positive control peptide) and TAT-AMP in delivering Cas9 protein in NK92 mCherry cells were demonstrated. At a concentration of 75 μM, the efficiency of TAT-HA2 (approximately 40%) was higher than that of TAT-AMP (…). Figure 6 (A), but it has high cytotoxicity, with a viable cell rate of only about 20% ( Figure 6 (B). When using the same concentrations of peptide 44, peptide 46, peptide 39, peptide 37, peptide 50, and peptide 35, the viable cell rate was consistently above 80%. Figure 6 (Middle B) Figure 7 The results show the number of edited cells obtained after delivery of Cas9 protein to NK92 mCherry cells with 75 μM TAT-HA2 (positive control peptide) and TAT-AMP. At a concentration of 75 μM, TAT-HA2 yielded the highest edited cell count of 1.7 × 10⁻⁶ cells. 4 One edited living cell, while peptide44 can yield up to 4.1 × 10⁻⁶ cells. 4The number of edited cells obtained by peptide44 was nearly 2.4 times that of TAT-HA2. Therefore, compared with TAT-HA2, delivery of Cas9 to NK92 mCherry cells using peptide44 yielded more edited cells.
[0076] Figure 8 The efficiency and cytotoxicity of 125 μM TAT-HA2 (positive control peptide) and TAT-AMP in delivering Cas9 protein to NK92 mCherry cells were shown. The TAT-HA2-mediated Cas9 delivery efficiency was 38%, peptide44's was 31.4%, and peptide46's was 14%. Figure 8 It contains A), and has no obvious cytotoxicity, while the viable cell rate of TAT-HA2 is only 14% ( Figure 8 (B)
[0077] Figure 9 The number of edited cells obtained after delivery of 125 μM TAT-HA2 (positive control peptide) and TAT-AMP to NK92 mCherry cells for Cas9 protein is shown. Using peptide44, peptide46, and TAT-HA2, the number of edited cells was 6.8 × 10⁻⁶. 4 3.1 × 10 4 The sum is 0.9 × 10 4 Among them, peptide44 was significantly superior to TAT-HA2, with the final number of edited cells being 7.6 times that of TAT-HA2. Although peptide46 did not have a significant advantage in efficiency, it had lower toxicity, so the final number of edited cells was also greater than that of TAT-HA2, being 3.4 times that of TAT-HA2.
[0078] 3. TAT-AMP delivery to RNP knockout Ai9 mouse NK cells tdTomato gene termination signal box stopcassette Primary NK cell extraction: NK cells were isolated from mouse spleens using the EasySep™ Mouse NK Cell Isolation Kit (STEMCELL #17855), and then expanded using complete culture medium containing 50 ng / mL IL-15 and 50 ng / mL IL-2 at 37°C and 5% CO2. Cell counting began on day 3 and was performed at a rate of 0.8–1.0 × 10⁻⁶ cells / day. 6 Cells were cultured at a density of / mL. Gene editing was performed on day 6 after the start of culture. (1) Dilute the Cas12a protein concentration to 25 μM using serum-free cell culture medium (RPMI 1640 medium); (2) Dilute crRNA to 100 μM with DNase-free / RNase-free water, aliquot and store at -80℃. The crRNA sequence is: UAAUUUCUACUCUUGUAGAUUCCAAACUCAUCAAUGUAUC (SEQ ID NO: 26). (3) Dissolve the peptides in PBS solution to 1 mM, filter sterilize using a 0.22 μm filter, aliquot and store at -80℃; (4) Dilute crRNA to a concentration of 20 μM using serum-free cell culture medium (RPMI 1640 medium); (5) Dilute the peptides to concentrations of 200 μM, 250 μM and 300 μM using serum-free cell culture medium (RPMI 1640 medium); (6) Mix the diluted Cas12a and diluted crRNA in equal volumes at a 1:1 ratio and let stand at room temperature for 20 min to form RNP. At this time, the concentration of crRNA is 10 μM and Cas12a is 12.5 μM, and the volume is generally not less than 10 μL. (7) Mix 10 μL of RNP with 10 μL of peptide, for a total of 20 μL, and let stand at room temperature for 5 min (at this time, the peptide concentrations are 100 μM, 125 μM, and 150 μM, respectively; crRNA is 5 μM; Cas12a is 6.25 μM; and RNP concentration is 5 μM). (8) Take 100-200K cells and centrifuge at 600×g for 3 min at room temperature to collect the cells. Wash the cells once with serum-free cell culture medium (RPMI 1640 medium) and centrifuge at 600×g for 3 min at room temperature to collect the cells; (9) Resuspend cells in 20 μL of RNP+ polypeptide and incubate at 37°C with 5% CO2 for 30 min; (10) Add 180 μL of complete culture medium (RPMI 1640 containing 10% FBS, 50 μM 2-mercaptoethanol, 1% Penicillin Streptomycin, 1% L-Glutamine, 1% Sodium Pyruvate, 1% Non-Essential Amino Acids (NEAA), 20 μM HEPES) to terminate the knockout, and collect the cells by centrifugation at 600×g for 3 min at room temperature; (11) The cells were resuspended in 200 μL of complete culture medium containing 50 ng / mL IL-15 and 50 ng / mL IL-2, and cultured in 96-well plates. The knockout efficiency was detected by flow cytometry on the fourth day. Figure 10 The efficiency and cytotoxicity of TAT-HA2 (positive control peptide) and TAT-AMP in delivering Cas12aRNP to primary NK cells of Ai9 mice were demonstrated. Delivery efficiency increased with increasing peptide concentration; at a final peptide concentration of 150 μM, TAT-HA2 showed an efficiency of 48.3%, while peptide46 showed an efficiency of 51.5%, slightly higher than TAT-HA2 (positive control peptide). Figure 10 A). Furthermore, TAT-HA2 caused significant cell damage, with cell viability below 20% at different peptide concentrations, while peptide 46 and peptide 44 caused less cell damage, with cell viability exceeding 70%. Figure 10 (B)
[0079] Figure 11 The results show the number of edited cells obtained after delivery of Cas12aRNP to primary NK cells of Ai9 mice with TAT-HA2 (positive control peptide) and TAT-AMP. At a peptide concentration of 150 μM, the number of edited cells obtained using peptide46 was 14.8 times that of TAT-HA2. Although peptide44 was less efficient than TAT-HA2 at various peptide concentrations, it had lower toxicity; therefore, using 100 μM, 125 μM, and 150 μM peptide44 yielded 5.6 × 10⁶ cells, respectively. 4 4.0×10 4 and 4.0×10 4 One edited live cell, while the corresponding concentration of TAT-HA2 yielded only 1.2 × 10⁻⁶ cells. 4 0.7×10 4 and 0.5×10 4 Each cell.
[0080] 4. TAT-AMP delivery of the stop cassette of the tdTomato gene in TAT-NLS-Cre knockout Ai9 mouse NK cells. (1) Dilute the TAT-NLS-Cre protein concentration to 20 μM using serum-free cell culture medium (RPMI 1640 medium); (2) Dissolve the peptides in PBS solution to 1 mM, filter sterilize using a 0.22 μm filter, aliquot and store at -80℃; (3) Take 200K cells and centrifuge at 600×g for 3 min at room temperature to collect the cells. Wash the cells once with serum-free cell culture medium (RPMI 1640 medium) and centrifuge at 600×g for 3 min at room temperature to collect the cells; (4) Add 1 μL of diluted TAT-NLS-Cre to the tube, then add 20 μL of cell suspension, and finally add 1 μL or 1.5 μL of 1 mM peptide. Incubate at 37°C and 5% CO2 for 30 min (at this time, the concentration of TAT-NLS-Cre is 1 μM and the concentration of peptide is 50 μM or 75 μM). (5) Add 180 μL of complete culture medium (RPMI 1640 containing 10% FBS, 50 μM 2-mercaptoethanol, 1% Penicillin Streptomycin, 1% L-Glutamine, 1% Sodium Pyruvate, 1% Non-Essential Amino Acids (NEAA), 20 μM HEPES) to terminate the knockout, and collect the cells by centrifugation at 600×g for 3 min at room temperature; (6) The cells were resuspended in 200 μL of complete culture medium containing 50 ng / mL IL-15 and 50 ng / mL IL-2, and cultured in 96-well plates. The knockout efficiency was detected by flow cytometry on the fourth day.
[0081] The amino acid sequence of the TAT-NLS-Cre protein is shown in SEQ ID NO: 27 below: GRKKRRQRRRPPAGTSSVSLKKKRKVSNLLTVHQNLPALPVDATSDEVRKNLMDMFRDRQAFSEHTWKMLLSVCRSWAAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNAVSLVMRRIRKENVDA GERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLLRIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVADDPNNYLFCRVRKNGVAAPSATSQLSTRALEGIFEATHRLIYGAKDDS GQRYLAWSGHSARVGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGDDTGSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKS AMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGMDELYK Figure 12 The efficacy and cytotoxicity of TAT-HA2 (positive control peptide) and TAT-AMP in delivering TAT-NLS-Cre to primary NK cells of Ai9 mice were demonstrated. At 50 μM peptide, the editing efficiencies of TAT-HA2, peptide46, and peptide44 were 65.6%, 91.1%, and 87.3%, respectively; at 75 μM, they were 82.2%, 96.8%, and 87.7%, respectively. The efficiencies of peptide46 and peptide44 were both higher than those of TAT-HA2 (…). Figure 12 (A). At peptide concentrations of 50 μM and 75 μM, the viability of peptide46 and peptide44 was >75%, significantly higher than that of TAT-HA2 (<25%). Figure 12 (B)
[0082] Figure 13The results show the number of edited cells obtained after gene editing of primary NK cells from Ai9 mice by delivering TAT-NLS-Cre using TAT-HA2 (positive control peptide) and TAT-AMP. Using 50 μM TAT-HA2 yielded 0.3 × 10⁻⁶ cells. 5 For each edited cell, the corresponding concentrations of peptide46 and peptide44 yielded 1.6 × 10⁻⁶ cells. 5 and 1.7×10 5 The number of edited cells was higher than that of TAT-HA2. When using 75 μM TAT-HA2, 0.3 × 10⁻⁶ cells were obtained. 5 For each edited cell, the corresponding concentrations of peptide46 and peptide44 yielded 1.5 × 10⁻⁶ cells. 5 and 1.5×10 5 The number of edited cells was significantly higher than that of TAT-HA2.
[0083] 5. TAT-AMP delivery to the muscle of Cas12a RNP knockout Ai9 mice tdTomato The stopcassette, a gene termination signal box.
[0084] (1) Dilute the Cas12a protein concentration to 25 μM using serum-free medium (RPMI 1640 medium); (2) Dilute crRNA to 100 μM with DNase-free / RNase-free water, aliquot and store at -80℃; knockout tdTomato The crRNA sequence used for the gene termination signal cassette is: UAAUUUCUACUCUUGUAGAUUCCAAACUCAUCAAUGUAUC (SEQ ID NO: 26) (3) Dissolve the peptides in PBS solution to 1 mM, filter sterilize using a 0.22 μm filter, aliquot and store at -80℃; (4) Dilute 100 μM crRNA to a concentration of 20 μM using serum-free medium (RPMI 1640 medium); (5) Dilute the 1 mM polypeptide carrier to a concentration of 150 μM using serum-free medium (RPMI 1640 medium); (6) Mix the diluted Cas12a and diluted crRNA in equal volumes at a 1:1 ratio and let stand at room temperature for 20 min (to prepare RNPs, at which point the concentration of crRNA is 10 μM and the concentration of Cas12a is 12.5 μM). (7) Mix RNP and peptide in equal volumes at a 1:1 ratio and let stand at room temperature for 5 min (at this time, the concentration of peptide is 75 μM, crRNA is 5 μM, Cas12a is 6.25 μM, and RNP is 5 μM). (8) Remove the Ai9 mouse from the cage, restrain it manually, and tilt its head downwards. Disinfect the abdominal skin with 75% ethanol solution, and anesthetize the mouse by intraperitoneal injection of 0.3% pentobarbital solution (50 mg / kg) in the left lower quadrant. (9) Disinfect the skin of the mouse's lower leg with 75% ethanol solution, and inject 50 μL of RNP+ polypeptide carrier into the lower leg muscle. After the injection, return the mouse to its cage for continued rearing; (10) Seven days later, the mice were euthanized, and the calf muscles were harvested and observed using the Perkin Elmer IVIS® Spectrum small animal imaging system. tdTomato The expression; The above TAT-AMP delivery to the muscle of Cas12a RNP knockout Ai9 mice tdTomato The process of gene termination signal box stop cassette is as follows: Figure 14 As shown in the middle route.
[0085] Figure 15 In mouse muscle, different peptide vectors were used to deliver Cas12a RNP knockout Ai9 mice. tdTomato The results of the gene termination cassette are shown in the figure. It can be seen that when using 75 μM peptide44, the fluorescence intensity of tdTomato expressed in tissues after delivery is higher than that of TAT-HA2, and the fluorescence intensity of peptide44 is twice that of TAT-HA2.
[0086] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," "some implementations," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0087] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.
Claims
1. A polypeptide, characterized in that, The amino acid sequence of the polypeptide is shown in SEQ ID NO: 2-23, or is a derived sequence having the same function as the amino acid sequence shown in SEQ ID NO: 2-23.
2. The polypeptide according to claim 1, characterized in that, The amino acid sequences of the polypeptide are shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO:
20. Optionally, the amino acid sequence of the polypeptide is shown in SEQ ID NO: 14 and SEQ ID NO:
16.
3. An isolated nucleic acid, characterized in that, The nucleic acid encodes the polypeptide as described in claim 1 or 2.
4. An expression carrier, characterized in that, The expression vector comprises the isolated nucleic acid as described in claim 3.
5. A host cell, characterized in that, The host cell comprises the expression vector of claim 4.
6. Use of the polypeptide of claim 1 or 2, the isolated nucleic acid of claim 3, the expression vector of claim 4, and the host cell of claim 5 in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system.
7. The use according to claim 6, characterized in that, The Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein; the Cre-loxP recombination system involves a Cre recombinase or a derivative of the Cre protein. Optionally, the CRISPR system effector proteins include one or more selected from Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl; Optionally, the derivatives of the Cas protein include a base editor and a bootstrap editor; Optionally, the derivatives of the Cre protein include one or more of TAT-NLS-Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
8. Use of the polypeptide of claim 1 or 2, the isolated nucleic acid of claim 3, the expression vector of claim 4, and the host cell of claim 5 in enhancing the gene editing efficiency of the CRISPR / Cas system or the Cre-loxP recombination system for NK cells.
9. The use according to claim 8, characterized in that, The Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein; Optionally, the CRISPR system effector proteins include one or more selected from Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl; Optionally, the derivatives of the Cas protein include a base editor and a bootstrap editor; Optionally, the Cre protein involved in the Cre-loxP recombination system is a Cre recombinase or a derivative of the Cre protein; Optionally, the derivatives of the Cre protein include one or more of TAT-NLS-Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
10. Use of the polypeptide of claim 1 or 2, the isolated nucleic acid of claim 3, the expression vector of claim 4, or the host cell of claim 5 in the preparation of reagents or kits for improving the gene editing efficiency of CRISPR / Cas systems or Cre-loxP recombination systems for NK cells.
11. The use according to claim 10, characterized in that, The Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein; the Cre-loxP recombination system involves a Cre recombinase or a derivative of the Cre protein. Optionally, the CRISPR system effector proteins include one or more selected from Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl; Optionally, the derivatives of the Cas protein include a base editor and a bootstrap editor; Optionally, the derivatives of the Cre protein include one or more of TAT-NLS-Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre.
12. A reagent or kit for improving the gene editing efficiency of NK cell CRISPR / Cas systems or Cre-loxP recombination systems, characterized in that, Includes at least one of the following: The polypeptide of claim 1 or 2, the isolated nucleic acid of claim 3, the expression vector of claim 4, and the host cell of claim 5.
13. The reagent or kit according to claim 12, characterized in that, The Cas protein involved in the CRISPR / Cas system is a CRISPR system effector protein or a derivative of the Cas protein; the Cre-loxP recombination system involves a Cre recombinase or a derivative of the Cre protein. Optionally, the CRISPR system effector proteins include one or more selected from Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl; Optionally, derivatives of the Cas protein include base editors and boot editors; The derivatives of the Cre protein include one or more of TAT-NLS-Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre; Optionally, the reagent or kit further includes delivery of cargo or TAT-NLS-Cre protein. The delivered goods include at least one of the following: (a) A CRISPR system effector protein, or a complex formed by sgRNA or crRNA targeting a gene and the CRISPR system effector protein; (b) Vectors expressing CRISPR system effector proteins, and sgRNA or crRNA targeting the target gene; (c) CRISPR system effector proteins, and vectors expressing sgRNA or crRNA that target the gene; (d) Vectors that co-express CRISPR system effector proteins and sgRNA or crRNA targeting target genes; Optionally, the amino acid sequence of the TAT-NLS-Cre protein is shown in SEQ ID NO:
27.
14. A method for improving gene editing efficiency in NK cell CRISPR / Cas systems or Cre-loxP recombination systems, characterized in that, Including the following (1) or (2): (1) The polypeptide of claim 1 or 2 is mixed with the cargo to be delivered to obtain a mixture; The mixture was introduced into NK cells; The delivered goods include at least one of the following: (a) A CRISPR system effector protein, or a complex formed by sgRNA or crRNA targeting a gene and the CRISPR system effector protein; (b) Vectors expressing CRISPR system effector proteins, and sgRNA or crRNA targeting the target gene; (c) CRISPR system effector proteins, and vectors expressing sgRNA or crRNA that target the gene; (d) Vectors that co-express CRISPR system effector proteins and sgRNA or crRNA targeting the target gene. (2) The polypeptide described in claim 1 or 2 is mixed with Cre recombinase or a derivative of Cre protein to obtain a mixture; The mixture was introduced into NK cells; The NK cells contain a pre-designed loxP site.
15. The method according to claim 14, characterized in that, The CRISPR system effector proteins include one or more selected from Cas12a, Cas9, Cas13, Cas3, Cas8, Csel, Csyl, Csn2, Cas4, Cas10, Csm2, Cmr5, and Fokl; the Cre protein derivatives include one or more selected from TAT-NLS-Cre, Cre, iCre, CreER, CreERT2, Split-Cre, and light-inducible Cre. Optionally, the amino acid sequence of the TAT-NLS-Cre protein is shown in SEQ ID NO: 27.
